Literature DB >> 17339421

TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help.

Sandra Hervas-Stubbs1, Aurélie Olivier, Florence Boisgerault, Nathalie Thieblemont, Claude Leclerc.   

Abstract

We investigated whether Toll-like receptor ligands (TLR-Ls) can bypass the requirement for CD4(+) T-cell help in the induction of fully efficient memory CD8(+) T cells (cytotoxic T lymphocytes [CTLs]). "Helpless" CTLs were induced by a synthetic CD8(+) T-cell epitope administered with TLR3-L and TLR9-L, but not with TLR2/6-L, TLR4-L, or TLR7-L. The up-regulation of MHC-I and costimulatory molecules by dendritic cells following TLR stimulation was not sufficient for the priming of "helpless" CTLs, which depended essentially on the induction of a strong IFN-alpha/beta response. The "helpless" CTLs induced by TLR-Ls differentiated into fully functional memory CTLs able to proliferate as well as their "helped" counterparts upon challenge, in the absence of CD4(+) T-cell help.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339421     DOI: 10.1182/blood-2006-10-053256

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 2.  Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection.

Authors:  Susan M Kaech; E John Wherry
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

3.  Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity.

Authors:  José V Pérez-Girón; Alan Belicha-Villanueva; Ebrahim Hassan; Sergio Gómez-Medina; Jazmina L G Cruz; Anja Lüdtke; Paula Ruibal; Randy A Albrecht; Adolfo García-Sastre; César Muñoz-Fontela
Journal:  J Immunol       Date:  2014-06-23       Impact factor: 5.422

Review 4.  Bystander T Cells: A Balancing Act of Friends and Foes.

Authors:  Sarah K Whiteside; Jeremy P Snook; Matthew A Williams; Janis J Weis
Journal:  Trends Immunol       Date:  2018-11-06       Impact factor: 16.687

5.  Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.

Authors:  Aaron E Foster; Aruna Mahendravada; Nicholas P Shinners; Wei-Chun Chang; Jeannette Crisostomo; An Lu; Mariam Khalil; Eva Morschl; Joanne L Shaw; Sunandan Saha; MyLinh T Duong; Matthew R Collinson-Pautz; David L Torres; Tania Rodriguez; Tsvetelina Pentcheva-Hoang; J Henri Bayle; Kevin M Slawin; David M Spencer
Journal:  Mol Ther       Date:  2017-07-08       Impact factor: 11.454

Review 6.  The multifaceted role of CD4(+) T cells in CD8(+) T cell memory.

Authors:  Brian J Laidlaw; Joseph E Craft; Susan M Kaech
Journal:  Nat Rev Immunol       Date:  2016-01-19       Impact factor: 53.106

7.  Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses.

Authors:  Céline Cousin; Marine Oberkampf; Tristan Felix; Pierre Rosenbaum; Robert Weil; Sylvie Fabrega; Valeria Morante; Donatella Negri; Andrea Cara; Gilles Dadaglio; Claude Leclerc
Journal:  Cell Rep       Date:  2019-01-29       Impact factor: 9.423

8.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

9.  In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.

Authors:  Deepak Assudani; Hyun-Il Cho; Nicholas DeVito; Norma Bradley; Esteban Celis
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 10.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.